1
|
Bouhniz OE, Zaied S, Naija L, Bettaieb I, Rahal K, Driss M, Kenani A. Association between HER2 and IL-6 genes polymorphisms and clinicopathological characteristics of breast cancer: significant role of genetic variability in specific breast cancer subtype. Clin Exp Med 2020; 20:427-436. [PMID: 32372374 DOI: 10.1007/s10238-020-00632-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2020] [Accepted: 04/24/2020] [Indexed: 12/12/2022]
Abstract
Clinical implications of single nucleotide polymorphisms (SNPs) in breast cancer have been explored to determine the impact of SNP in modulating the pathogenesis of breast cancer. This study aimed to evaluate the association between HER2 (rs2517956) and (IL-6) (rs1800795 and rs2069837) and clinicopathological characteristics in HER2-positive and HER2-negative breast cancer in Tunisian women. A retrospective cohort study included 273 patients. Genomic DNA was extracted from peripheral blood samples, and genotyping of selected SNP was performed by PCR-RFLP assays. Statistical analysis was then carried out to assess genotypic frequencies and genetic association in relation to breast cancer subtypes. SHEsis software was applied to IL-6 haplotypic structure analysis. The distribution of genotype frequencies of rs2517956, rs1800795 and rs2069837 showed no statistically difference between HER2-positive and HER2-negative breast cancer. HER2 (rs2517956) was associated with tumor size (p = 0.01) and age at diagnosis (p = 0.02) in HER2-negative breast cancers, but no significant association was observed in HER2-positive breast cancer. For IL-6 gene, none of the clinicopathological parameters were associated with rs1800795 and rs2069837 in both breast cancer subtypes (p > 0.05). SHEsis analysis revealed a high linkage disequilibrium between rs1800795 and rs2069837; differences in the distribution of IL-6 two loci haplotypes were statistically negative between HER2-positive and HER2-negative breast cancer (p = 0.20) which confirmed no association with HER2 overexpression. This study demonstrates that rs2517956 is associated with clinicopathological characteristics in HER2-negative breast cancer, which could have a differential prognostic role compared to HER2-positive breast cancer.
Collapse
Affiliation(s)
- Om Elez Bouhniz
- Research Laboratory "Environment, Inflammation, Signaling and Pathologies" (LR18ES40), Faculty of Medicine of Monastir, University of Monastir, Monastir, Tunisia.
| | - Sonia Zaied
- Research Laboratory "Environment, Inflammation, Signaling and Pathologies" (LR18ES40), Faculty of Medicine of Monastir, University of Monastir, Monastir, Tunisia.,Department of Clinical Oncology, CHU Fattouma Bourguiba, Monastir, Tunisia
| | - Lamia Naija
- Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia
| | - Ilhem Bettaieb
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia
| | - Khaled Rahal
- Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia
| | - Maha Driss
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia
| | - Abderraouf Kenani
- Research Laboratory "Environment, Inflammation, Signaling and Pathologies" (LR18ES40), Faculty of Medicine of Monastir, University of Monastir, Monastir, Tunisia
| |
Collapse
|
2
|
Ottaiano A, Circelli L, Lombardi A, Scala S, Martucci N, Galon J, Buonanno M, Scognamiglio G, Botti G, Hermitte F, Savarese G, D'Amore L, Tatangelo F, Di Mauro A, Liguori G, Trotta AM, Napolitano M, Capozzi M, Tafuto S, Perri F, La Rocca A, Caraglia M, Nasti G. Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. Cell Death Dis 2020; 11:275. [PMID: 32332709 PMCID: PMC7181838 DOI: 10.1038/s41419-020-2480-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 04/10/2020] [Accepted: 04/10/2020] [Indexed: 01/08/2023]
Abstract
Genetics and immunologic dynamics pushing the evolution of colorectal cancer (CRC) from the primary tumor to the metastases are largely unknown; cancer heterogeneity makes challenging both therapy and mechanistic studies. We selected patients developing CRC with lung-limited metastatic disease as only illness during their life in order to find any relevant genotype–phenotype relationship. Analysis of 523 cancer-relevant genes and of immune cells infiltration in primary and metastatic tissues revealed atypical genomic trajectories (TMB decrease, KRAS and SMAD4 regressive mutations), specific genetic events (ERBB2 point mutations) and scarce T-cell infiltration. These insights provide novel information in oligometastatic CRC biology and new perspectives for cancer monitoring and anti-cancer therapeutic strategies.
Collapse
Affiliation(s)
- Alessandro Ottaiano
- Department of Abdominal Oncology, SSD-Innovative Therapies for Abdominal Cancers, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", , Via M. Semmola, 80131, Naples, Italy.
| | - Luisa Circelli
- AMES-Centro Polidiagnostico Strumentale, Srl, Naples, Italy
| | - Angela Lombardi
- Department of Precision Medicine, University of Campania "L. Vanvitelli" , Via L. De Crecchio, 7, 80138, Naples, Italy
| | - Stefania Scala
- Functional Genomics, Istituto Nazionale Tumori, IRCCS "G. Pascale" , Via M. Semmola, 80131, Naples, Italy
| | - Nicola Martucci
- Department of Thoracic Surgery and Oncology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale" , Via M. Semmola, 80131, Naples, Italy
| | - Jerome Galon
- INSERM, Laboratory of Integrative Cancer Immunology, Equipe Labellisée Ligue Contre le Cancer, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006, Paris, France
| | - Manuela Buonanno
- Center for Radiological Research, Department of Radiation Oncology, Columbia University Medical Center, New York, New York, NY, USA
| | - Giosuè Scognamiglio
- Department of Pathology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale",, Via M. Semmola, 80131, Naples, Italy
| | - Gerardo Botti
- Department of Pathology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale",, Via M. Semmola, 80131, Naples, Italy
| | | | | | - Luigi D'Amore
- AMES-Centro Polidiagnostico Strumentale, Srl, Naples, Italy
| | - Fabiana Tatangelo
- Department of Pathology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale",, Via M. Semmola, 80131, Naples, Italy
| | - Annabella Di Mauro
- Department of Pathology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale",, Via M. Semmola, 80131, Naples, Italy
| | - Giuseppina Liguori
- Department of Pathology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale",, Via M. Semmola, 80131, Naples, Italy
| | - Anna Maria Trotta
- Functional Genomics, Istituto Nazionale Tumori, IRCCS "G. Pascale" , Via M. Semmola, 80131, Naples, Italy
| | - Maria Napolitano
- Functional Genomics, Istituto Nazionale Tumori, IRCCS "G. Pascale" , Via M. Semmola, 80131, Naples, Italy
| | - Monica Capozzi
- Department of Abdominal Oncology, Clinical and Experimental Abdominal Oncology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy
| | - Salvatore Tafuto
- Department of Abdominal Oncology, Clinical and Experimental Abdominal Oncology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy
| | - Francesco Perri
- Head and Neck Cancer Medical Oncology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy
| | - Antonello La Rocca
- Department of Thoracic Surgery and Oncology, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale" , Via M. Semmola, 80131, Naples, Italy
| | - Michele Caraglia
- Department of Precision Medicine, University of Campania "L. Vanvitelli" , Via L. De Crecchio, 7, 80138, Naples, Italy.,Biogem Scarl, Institute of Genetic Research, Laboratory of Precision and Molecular Oncology, Ariano Irpino, Italy
| | - Guglielmo Nasti
- Department of Abdominal Oncology, SSD-Innovative Therapies for Abdominal Cancers, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", , Via M. Semmola, 80131, Naples, Italy
| |
Collapse
|